Skip to content

Stock Symbol: RCAR

RenovaCare
Cell Renewal, Naturally.
RenovaCareRenovaCare
  • Corporate
    • About Us
    • Our Team
  • Science
    • Our Technology
    • Publications
  • Gallery
    • Our Photos
    • Our Videos
  • News
    • Press Releases
    • Media Coverage
    • Press Kit / Media
  • Investors
    • Overview
    • Email Alerts
    • SEC Filings
    • Investor FAQs
    • Corporate Governance
  • Contact
    • Contact Us
Search:
  • Corporate
    • About Us
    • Our Team
  • Science
    • Our Technology
    • Publications
  • Gallery
    • Our Photos
    • Our Videos
  • News
    • Press Releases
    • Media Coverage
    • Press Kit / Media
  • Investors
    • Overview
    • Email Alerts
    • SEC Filings
    • Investor FAQs
    • Corporate Governance
  • Contact
    • Contact Us

Daily Archives: May 6, 2021

FDA Grants RenovaCare Full IDE Approval for Safety and Feasibility Clinical Trial

News & Events, Press ReleasesBy amit.damaakMay 6, 2021

Roseland, NJ – May 6th, 2021 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), today announced that its IDE application has been granted full approval by the FDA, enabling RenovaCare to conduct a clinical trial to evaluate the safety and feasibility of its SkinGun™ and CellMist™ System for the treatment of burn wounds.

© Copyright RenovaCare, Inc. Third party logos do not represent affiliation or endorsement.
RenovaCare products are under development and not approved for sale in the United States.
Results may vary from person to person.

Disclaimer & Privacy Policy | Contact |

Go to Top